← Leaderboards
Thomas Anchordoquy
University Of Colorado Denver
$4,579,186
Attributed
$6,559,848
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $664.4K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,559,848 · 7
By mechanism
R01$6,544,848 · 6
R13$15,000 · 1
Top collaborators
- Michael W. Graner9 shared
- Dmitri Simberg2 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Maranke I. Koster$6,249,820
- Edwin Liu$1,411,508
- John A Desisto$319,265
- Michael W. Graner$2,952,043
- Sally J Rogers$35,933,937
Others in their field
Top investigators on “Drug Delivery Systems”
- Wafaa M. El-Sadr · Columbia University Health Sciences$101,800,876
- Myron S Cohen · Family Health International$101,800,876
- Gerald Van Belle · University Of Washington$48,120,734
- David Heimbrook · Leidos Biomedical Research, Inc.$47,325,954
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$38,382,452
- Martin Friedlander · Scripps Research Institute$36,319,942
Research focus
Drug Delivery SystemsParticleNanoparticleBaseTumorIn VivoLipidsPharmaceutical PreparationsUptakeTissuesMouse ModelAntibodiesLigandsBloodBlood CirculationParticulateImmunocompetentMalignant NeoplasmsBiodistributionExhibitsDrug FormulationsLiposomesMicrornasPathway Interactions
Grant awards (22)
Reducing Off-Target Accumulation of Chemotherapeutic Nanomedicines$375,134
R01 · FY2025 · CA · contact PI
Mechanisms and Barriers in Nanomedicine-2023$15,000
R13 · FY2023 · EB
Exploiting an endogenous transcytotic pathway for oral drug delivery$472,274
R01 · FY2021 · GM · contact PI
Exploiting an endogenous transcytotic pathway for oral drug delivery$472,274
R01 · FY2020 · GM · contact PI
Exploiting an endogenous transcytotic pathway for oral drug delivery$498,809
R01 · FY2019 · GM · contact PI
Exploiting an endogenous transcytotic pathway for oral drug delivery$96,970
R01 · FY2019 · GM · contact PI
Exploiting an endogenous transcytotic pathway for oral drug delivery$498,808
R01 · FY2018 · GM · contact PI
Tumor-Homing Exosomes for Drug Delivery$388,750
R01 · FY2016 · EB · contact PI
Tumor-Homing Exosomes for Drug Delivery$380,975
R01 · FY2015 · EB · contact PI
Tumor-Homing Exosomes for Drug Delivery$375,976
R01 · FY2014 · EB · contact PI
Exploiting Cholesterol Nanodomains to Improve Targeting$285,746
R01 · FY2014 · GM · contact PI
Tumor-Homing Exosomes for Drug Delivery$386,354
R01 · FY2013 · EB · contact PI
Exploiting Cholesterol Nanodomains to Improve Targeting$278,076
R01 · FY2013 · GM · contact PI
Exploiting Cholesterol Nanodomains to Improve Targeting$288,162
R01 · FY2012 · GM · contact PI
Exploiting Cholesterol Nanodomains to Improve Targeting$288,162
R01 · FY2011 · GM · contact PI
Formulation of Synthetic Vectors as Lyophilized Products$234,410
R01 · FY2009 · EB · contact PI
Formulation of Synthetic Vectors as Lyophilized Products$234,410
R01 · FY2008 · EB · contact PI
Formulation of Synthetic Vectors as Lyophilized Products$235,517
R01 · FY2007 · EB · contact PI
Formulation of Synthetic Vectors as Lyophilized Products$242,550
R01 · FY2006 · EB · contact PI
LYOPHILIZATION OF NONVIRAL GENE DELIVERY SYSTEMS$159,515
R01 · FY2002 · GM
LYOPHILIZATION OF NONVIRAL GENE DELIVERY SYSTEMS$170,275
R01 · FY2001 · GM
LYOPHILIZATION OF NONVIRAL GENE DELIVERY SYSTEMS$181,701
R01 · FY2000 · GM